The EU has approved a Luxembourg firm’s acquisition of a surgical bleeding solutions unit, concluding it poses no threat to competition.
EU clears biosurgery merger, says competition concerns are unfounded
www.brusselstimes.com
September 23, 2026 at 8:32 PM
The EU has approved a Luxembourg firm’s acquisition of a surgical bleeding solutions unit, concluding it poses no threat to competition.
Peer-reviewed 411-patient study reports low infection rates with MyriadTM in complex soft tissue reconstruction
Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction AUCKLAND, New Zealand,…
Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction AUCKLAND, New Zealand,…
Peer-reviewed 411-patient study reports low infection rates with MyriadTM in complex soft tissue reconstruction
Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction AUCKLAND, New Zealand, Sept. 6, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company,...
news-area.com
September 7, 2026 at 12:58 PM
Peer-reviewed 411-patient study reports low infection rates with MyriadTM in complex soft tissue reconstruction
Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction AUCKLAND, New Zealand,…
Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction AUCKLAND, New Zealand,…
📢 Biosurgery is #hiring a Associate Director, Global Health Economics Market Access!
🌎 6041
🔗 http://jbs.ink/6n8FmUNWctHw
#jobalert #jobsearch #familyofficejobs #machinelearning #marketing
🌎 6041
🔗 http://jbs.ink/6n8FmUNWctHw
#jobalert #jobsearch #familyofficejobs #machinelearning #marketing
August 17, 2026 at 5:15 AM
📢 Biosurgery is #hiring a Associate Director, Global Health Economics Market Access!
🌎 6041
🔗 http://jbs.ink/6n8FmUNWctHw
#jobalert #jobsearch #familyofficejobs #machinelearning #marketing
🌎 6041
🔗 http://jbs.ink/6n8FmUNWctHw
#jobalert #jobsearch #familyofficejobs #machinelearning #marketing
Aroa Biosurgery Strengthens U.S. Commercial Team with New Appointments#New_Zealand#Auckland#Aroa_Biosurgery#Michael_Lynskey#Mike_Falcon
Aroa Biosurgery Strengthens U.S. Commercial Team with New Appointments
Aroa Biosurgery Limited has announced the appointments of Michael Lynskey and Mike Falcon to its U.S. team, enhancing its commercial strategy.
third-news.com
July 28, 2026 at 5:12 AM
Aroa Biosurgery Strengthens U.S. Commercial Team with New Appointments#New_Zealand#Auckland#Aroa_Biosurgery#Michael_Lynskey#Mike_Falcon
Feed: "Stockhead"
By: Stockhead TV on Tuesday, July 14, 2026
By: Stockhead TV on Tuesday, July 14, 2026
Long Shortz with Aroa Biosurgery: Symphony remains well positioned under CMS proposal
The latest US reimbursement updates for Symphony and why the proposed CMS changes are significant for the outpatient wound care market.
stockhead.com.au
July 14, 2026 at 11:20 PM
Feed: "Stockhead"
By: Stockhead TV on Tuesday, July 14, 2026
By: Stockhead TV on Tuesday, July 14, 2026
Biosurgery Market Trends | Industry Analysis & Insights 2035 | WiseGuyReports www.wiseguyreports.com/reports/bio-...
www.wiseguyreports.com
July 14, 2026 at 9:21 AM
Biosurgery Market Trends | Industry Analysis & Insights 2035 | WiseGuyReports www.wiseguyreports.com/reports/bio-...
Latham & Watkins Advises EQT in Acquisition of TachoSil® Biosurgery Business from Corza Medical
EQT has announced that EQT X has agreed to acquire Corza Biosurgery from Corza Medical, comprising... The post Latham & Watkins Advises EQT in Acquisition of TachoSil® Biosurgery Business from Corza…
EQT has announced that EQT X has agreed to acquire Corza Biosurgery from Corza Medical, comprising... The post Latham & Watkins Advises EQT in Acquisition of TachoSil® Biosurgery Business from Corza…
Latham & Watkins Advises EQT in Acquisition of TachoSil® Biosurgery Business from Corza Medical
EQT has announced that EQT X has agreed to acquire Corza Biosurgery from Corza Medical, comprising... The post Latham & Watkins Advises EQT in Acquisition of TachoSil® Biosurgery Business from Corza Medical appeared first on Legal Desire Media and Insights .
news-area.com
July 8, 2026 at 9:29 PM
Latham & Watkins Advises EQT in Acquisition of TachoSil® Biosurgery Business from Corza Medical
EQT has announced that EQT X has agreed to acquire Corza Biosurgery from Corza Medical, comprising... The post Latham & Watkins Advises EQT in Acquisition of TachoSil® Biosurgery Business from Corza…
EQT has announced that EQT X has agreed to acquire Corza Biosurgery from Corza Medical, comprising... The post Latham & Watkins Advises EQT in Acquisition of TachoSil® Biosurgery Business from Corza…
EQT to Acquire Corza Medical's TachoSil® Biosurgery Business for Growth in Surgical Solutions#Sweden#EQT#Stockholm#Corza_Medical#TachoSil
EQT to Acquire Corza Medical's TachoSil® Biosurgery Business for Growth in Surgical Solutions
EQT is set to acquire Corza Biosurgery, known for TachoSil®, enhancing surgical outcomes. This transaction aims to drive growth and innovation in the biosurgery sector.
third-news.com
July 7, 2026 at 7:01 AM
EQT to Acquire Corza Medical's TachoSil® Biosurgery Business for Growth in Surgical Solutions#Sweden#EQT#Stockholm#Corza_Medical#TachoSil
GTCR Completes Sale of Corza Medical's Biosurgery Unit to EQT for Strategic Growth#United_States#Chicago#GTCR#Corza_Medical#TachoSil
GTCR Completes Sale of Corza Medical's Biosurgery Unit to EQT for Strategic Growth
GTCR has signed an agreement to sell Corza Medical's Biosurgery unit to EQT, allowing Corza to focus on other surgical business sectors while enhancing growth strategies.
third-news.com
July 7, 2026 at 6:08 AM
GTCR Completes Sale of Corza Medical's Biosurgery Unit to EQT for Strategic Growth#United_States#Chicago#GTCR#Corza_Medical#TachoSil
FDA Approves Second Fly Species for Maggot Therapy
#FDA #maggottherapy #woundtreatment
https://singulism.com/en/2026-06-18-fda-approves-second-maggot-therapy-species
#FDA #maggottherapy #woundtreatment
https://singulism.com/en/2026-06-18-fda-approves-second-maggot-therapy-species
FDA Approves Second Fly Species for Maggot Therapy
The FDA has approved Lucilia cuprina for maggot-based wound treatment, granting Cuprina Holdings exclusive access to the biosurgery market.
singulism.com
June 23, 2026 at 9:43 PM
FDA Approves Second Fly Species for Maggot Therapy
#FDA #maggottherapy #woundtreatment
https://singulism.com/en/2026-06-18-fda-approves-second-maggot-therapy-species
#FDA #maggottherapy #woundtreatment
https://singulism.com/en/2026-06-18-fda-approves-second-maggot-therapy-species
RN Biosurgery Clinical Educator-Boston - Parsippany, New Jersey, United States of America Job educativ.net/jobs/job/60964...
June 23, 2026 at 9:24 PM
RN Biosurgery Clinical Educator-Boston - Parsippany, New Jersey, United States of America Job educativ.net/jobs/job/60964...
Feed: "Stockhead"
By: Tim Boreham on Thursday, June 11, 2026
By: Tim Boreham on Thursday, June 11, 2026
Health Kick Podcast: Aroa prepares for next growth phase on record revenue
Aroa Biosurgery (ASX:ARX) is focused on its next phase of growth. CFO James Agnew joins Tim Boreham to discuss.
stockhead.com.au
June 12, 2026 at 3:01 AM
Feed: "Stockhead"
By: Tim Boreham on Thursday, June 11, 2026
By: Tim Boreham on Thursday, June 11, 2026
Biosurgery Clinical Nurse Educator Winston-Salem - Parsippany, New Jersey, United States of America Job educativ.net/jobs/job/60306...
June 9, 2026 at 11:13 PM
Biosurgery Clinical Nurse Educator Winston-Salem - Parsippany, New Jersey, United States of America Job educativ.net/jobs/job/60306...
Feed: "Stockhead"
By: Stockhead TV on Wednesday, May 27, 2026
By: Stockhead TV on Wednesday, May 27, 2026
Long Shortz with Aroa Biosurgery: ARX delivers breakout FY26 results
Aroa (ASX:ARX) has delivered breakout FY26 results, with record revenue, strong EBITDA growth and rising momentum from its Myriad product portfolio.
stockhead.com.au
May 28, 2026 at 12:32 AM
Feed: "Stockhead"
By: Stockhead TV on Wednesday, May 27, 2026
By: Stockhead TV on Wednesday, May 27, 2026
📢 Host Tylah Tully sits down with Aroa Biosurgery (ASX:ARX) founder and CEO Brian Ward to unpack the company’s breakout FY26 results, including record revenue growth, strong EBITDA performance and accelerating momentum from its Myriad product line.
ARX delivers breakout FY26 results
www.theaustralian.com.au
May 27, 2026 at 4:33 PM
📢 Host Tylah Tully sits down with Aroa Biosurgery (ASX:ARX) founder and CEO Brian Ward to unpack the company’s breakout FY26 results, including record revenue growth, strong EBITDA performance and accelerating momentum from its Myriad product line.
Feed: "Stockhead"
By: Special Report on Tuesday, May 26, 2026
By: Special Report on Tuesday, May 26, 2026
Aroa beats FY26 guidance as Myriad drives 54% growth surge
Soft-tissue repair company Aroa Biosurgery (ASX:ARX) has delivered a strong FY26 result, beating revenue and earnings guidance.
stockhead.com.au
May 27, 2026 at 12:17 AM
Feed: "Stockhead"
By: Special Report on Tuesday, May 26, 2026
By: Special Report on Tuesday, May 26, 2026
Feed: "Stockhead"
By: Tim Boreham on Tuesday, May 26, 2026
By: Tim Boreham on Tuesday, May 26, 2026
Biocurious: Aroa brings a touch of ‘magic’ to the US$3 billion woundcare sector
On the back of stellar financial results, Aroa Biosurgery reckons it has only just begun to penetrate the capacious US market.
stockhead.com.au
May 27, 2026 at 12:16 AM
Feed: "Stockhead"
By: Tim Boreham on Tuesday, May 26, 2026
By: Tim Boreham on Tuesday, May 26, 2026